News

Discovery Could Lead to Anti-Clotting Drugs With Less Risk of Bleeding

29.10.20132066

Researchers at the University of Illinois at Chicago have discovered a molecular switch that causes small, beneficial clots that stop bleeding to enlarge further during wound healing.

Inhibiting a Single Protein Could Improve Treatment of Atherosclerosis

28.10.20131884

Researchers of the Spanish research council (Consejo Superior de Investigaciones Cient?ficas, CSIC) and the Centro Nacional de Investigaciones Cardiovasculares (CNIC) have discovered that inhibiting the protein Rcan1 in mice reduces the burden of atherosclerosis, one of the commonest cardiovascular diseases.

Catheter Ablation vs. Antiarrhythmic Drug Treatment of Persistent Atrial Fibrillation: A Multicenter, Randomized, Controlled Trial (SARA Study)

25.10.20131852

Is radiofrequency catheter ablation (RFCA) more effective than antiarrhythmic drug therapy (AADT) for preventing persistent atrial fibrillation (AF)?

6-Minute Walk Time Predicts TAVI Outcome

24.10.20132044

Among patients with chronic obstructive pulmonary disease (COPD) undergoing transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis, worse exercise capacity at baseline was associated with poorer outcomes, researchers found.

Association Between Influenza Vaccination and Cardiovascular Outcomes in High-Risk Patients

23.10.20131920

Among nontraditional cardiovascular risk factors, recent influenzalike infection is associated with fatal and nonfatal atherothrombotic events.

Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial

22.10.20131906

Рatients with Marfan syndrome have an increased risk of life-threatening aortic complications, mostly preceded by aortic dilatation. Treatment with losartan, an angiotensin-II receptor-1 blocker, may reduce aortic dilatation rate in Marfan patients.

Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis

21.10.20131772

The clinical armamentarium for anticoagulation has expanded substantially since the recent approval of dabigatran, rivaroxaban and apixaban for the prevention of stroke in atrial fibrillation.